

## ELEKTA INTRODUCES NEW IMAGE GUIDED STEREOTACTIC SOLUTION TO EXPAND PRODUCT RANGE FOR TREATING CANCERS IN THE BRAIN, SPINE AND BODY

## PRESS RELEASE

Stockholm, Sweden, April 20, 2006

# Specialized tools designed to help neurosurgeons treat serious disease more aggressively than ever, with full confidence.

Elekta will showcase a complete portfolio of stereotactic solutions at the upcoming annual meeting of the American Association of Neurological Surgeons (AANS) April 22–27, at the Moscone Convention Center in San Francisco, California.

Elekta demonstrates a continued leadership as the only stereotatic solutions provider with specialized tools for treating cancer and other serious diseases in the brain, spine and body. Elekta introduces the new Elekta Axesse<sup>™</sup>, the world's only 6D robotic image guided radiosurgery system optimized for treatment of the spine. The new Elekta Axesse system uses exclusive stereotactic technology and true three-dimensional (3D) imaging to ensure fast, efficient and accurate treatment for the patient.

In addition, Elekta will feature Leksell Gamma Knife<sup>®</sup>, the only gold standard for treating indications of the brain and the world's only dedicated system for non-invasive radiosurgery. Patients are attracted by its gentle nature, short procedure time and documented clinical results. The patient often leaves the hospital the same day and returns to daily life.

"Neurosurgeons possess rare, important skills and choosing the right stereotactic systems enables them to expand those skills," says Jim Rose, Elekta Vice President of Marketing for the Americas. "Elekta's stereotactic systems offer the unrivaled precision neurosurgeons need to treat cancer and other serious disease more aggressively than ever, without increasing risk to healthy tissue."

Also, Elekta will exhibit several other complementary products for the neurosurgery market, including:

- Leksell<sup>®</sup> Stereotactic System, the most widely used coordinate frame in the world. It sets standards for accuracy, reliability, versatility and ease-of-use. Elekta's 3D reference and positioning system is ideal for functional and stereotactic neurosurgery.
- Elekta Neuromag<sup>®</sup>, the world's most advanced magnetoencephalography (MEG) system, represents a new standard for combined MEG/EEG devices. Using MEG, it is possible to determine the function of different parts of the brain for each specific patient in the current stage of his or her development.

"Our world-leading portfolio of stereotactic solutions also allows neurosurgeons to enjoy long-term profitability and strong collaboration with the oncology department," says Rose. "With this portfolio, neurosurgeons can build a Stereotactic Center of Excellence that aligns perfectly with their clinical plans and business objectives."



\* \* \* \* \* \*

### For further information, please contact:

Peter Ejemyr Group VP Corporate Communications, Elekta AB Tel: +46 733 611 000 (mobile) e-mail: peter.ejemyr@elekta.com

#### Media Inquiries:

Michelle Lee PR and Advertising Manager, Elekta, Inc. Tel: +1 770-670-2447 e-mail: michelle.lee@elekta.com

#### About Elekta

Elekta is an international medical-technology Group, providing meaningful clinical solutions, comprehensive information systems and services for improved cancer care and management of brain disorders. All of Elekta's solutions employ non-invasive or minimally invasive techniques and are therefore clinically effective, gentle on the patient and cost-effective.

Clinical solutions include among others Leksell Gamma Knife<sup>®</sup> for non-invasive treatment of brain disorders and Elekta Synergy<sup>®</sup> for image guided radiation therapy (IGRT). Following the acquisition of IMPAC Medical Systems Inc. in April 2005, the Elekta Group is the world's largest supplier of oncology software.

Elekta's systems and solutions are used at over 3,000 hospitals around the world to treat cancer and manage clinical operations as well as to diagnose and treat brain disorders, including tumors, vascular malformations and functional disorders.

With approx. 1,850 employees, Elekta's corporate headquarter is located in Stockholm, Sweden and the company is listed on the Stockholm Stock Exchange under the ticker EKTAb. For more information about Elekta, please visit www.elekta.com.